Lavinia Morosi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lavinia Morosi has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Massimo Zucchetti
Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
20 shared publications - Maurizio D'Incalci
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
14 shared publications - Roberta Frapolli
Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy
11 shared publications - Enrico Davoli
Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
9 shared publications - Fulvio Magni
Proteomics and Metabolomics Unit, Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
6 shared publications Silvia Giordano
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Laboratory of Mass Spectrometry
6 shared publications
Latest Publications
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (8) , 1363-1375
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel.
- 1 January 2020
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (8) , 1363-1375
Open AccessQuantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel.
- Open Access
- 6 December 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (12) , 658
Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs
One of the goals of the pharmaceutical sciences is the amelioration of targeted drug delivery. In this context, nanocarrier-dependent transportation represents an ideal method for confronting a broad range of human disorders. In this study, we investigated the possibility of improving the selective release of the anti-cancer drug paclitaxel (PTX) in the gastro-intestinal tract by encapsulating it into the biodegradable nanoparticles made by FDA-approved poly(lactic-co-glycolic acid) (PLGA) and coated with polyethylene glycol to improve their stability (PLGA-PEG-NPs). Our study was performed by combining the synthesis and characterization of the nanodrug with in vivo studies of pharmacokinetics after oral administration in mice. Moreover, fluorescent PLGA-nanoparticles (NPs), were tested both in vitro and in vivo to observe their fate and biodistribution. Our study demonstrated that PLGA-NPs: (1) are stable in the gastric tract; (2) can easily penetrate inside carcinoma colon 2 (CaCo2) cells; (3) reduce the PTX absorption from the gastrointestinal tract, further limiting systemic exposure; (4) enable PTX local targeting. At present, the oral administration of biodegradable nanocarriers is limited because of stomach degradation and the sink effect played by the duodenum. Our findings, however, exhibit promising evidence towards our overcoming these limitations for a more specific and safer strategy against gastrointestinal disorders.
- 6 December 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (12) , 658
Open AccessMonitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs
One of the goals of the pharmaceutical sciences is the amelioration of targeted drug delivery. In this context, nanocarrier-dependent transportation represents an ideal method for confronting a broad range of human disorders. In this study, we investigated the possibility of improving the selective release of the anti-cancer drug paclitaxel (PTX) in the gastro-intestinal tract by encapsulating it into the biodegradable nanoparticles made by FDA-approved poly(lactic-co-glycolic acid) (PLGA) and coated with polyethylene glycol to improve their stability (PLGA-PEG-NPs). Our study was performed by combining the synthesis and characterization of the nanodrug with in vivo studies of pharmacokinetics after oral administration in mice. Moreover, fluorescent PLGA-nanoparticles (NPs), were tested both in vitro and in vivo to observe their fate and biodistribution. Our study demonstrated that PLGA-NPs: (1) are stable in the gastric tract; (2) can easily penetrate inside carcinoma colon 2 (CaCo2) cells; (3) reduce the PTX absorption from the gastrointestinal tract, further limiting systemic exposure; (4) enable PTX local targeting. At present, the oral administration of biodegradable nanocarriers is limited because of stomach degradation and the sink effect played by the duodenum. Our findings, however, exhibit promising evidence towards our overcoming these limitations for a more specific and safer strategy against gastrointestinal disorders.
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e59
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
Evidences from animal models seem to suggest that minimally invasive surgery may enhance cisplatin diffusion when the drug is administered in the context of post-operative hyperthermic intraperitoneal chemotherapy (HIPEC). The present study evaluates the cisplatin pharmacokinetic profile in a prospective series of women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS). Cisplatin levels were assessed at 0, 20, 40, 60, and 120 minutes in: 1) blood samples, 2) peritoneal perfusate, and 3) peritoneal biopsies at the end of HIPEC. Median Cmax has been used to identify women with high and low drug levels. Progression-free survival (PFS) was calculated as the time elapsed between SCS+HIPEC and secondary recurrence or last follow-up visit. Nine (45.0%) women received MI-SCS, and 11 (55.0%) O-SCS. At 60 minutes, median cisplatin Cmax in peritoneal tissue was higher in patients treated with MI-SCS compared to O-SCS (Cmax=8.262 μg/mL vs. Cmax=4.057 μg/mL). Furthermore, median cisplatin plasma Cmax was higher in patients treated with MI-SCS compared to O-SCS (Cmax=0.511 vs. Cmax=0.254 μg/mL; p-value=0.012) at 120 minutes. With a median follow-up time of 24 months, women with higher cisplatin peritoneal Cmax showed a longer PFS compared to women with low cisplatin peritoneal levels (2-years PFS=70% vs. 35%; p-value=0.054). We demonstrate for the first time that minimally invasive route enhances cisplatin peritoneal tissue uptake during HIPEC, further evaluations are needed to confirm the correlation between peritoneal cisplatin levels after HIPEC and survival. ClinicalTrials.gov Identifier: NCT01539785.
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e59
Open AccessPharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
Evidences from animal models seem to suggest that minimally invasive surgery may enhance cisplatin diffusion when the drug is administered in the context of post-operative hyperthermic intraperitoneal chemotherapy (HIPEC). The present study evaluates the cisplatin pharmacokinetic profile in a prospective series of women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS). Cisplatin levels were assessed at 0, 20, 40, 60, and 120 minutes in: 1) blood samples, 2) peritoneal perfusate, and 3) peritoneal biopsies at the end of HIPEC. Median Cmax has been used to identify women with high and low drug levels. Progression-free survival (PFS) was calculated as the time elapsed between SCS+HIPEC and secondary recurrence or last follow-up visit. Nine (45.0%) women received MI-SCS, and 11 (55.0%) O-SCS. At 60 minutes, median cisplatin Cmax in peritoneal tissue was higher in patients treated with MI-SCS compared to O-SCS (Cmax=8.262 μg/mL vs. Cmax=4.057 μg/mL). Furthermore, median cisplatin plasma Cmax was higher in patients treated with MI-SCS compared to O-SCS (Cmax=0.511 vs. Cmax=0.254 μg/mL; p-value=0.012) at 120 minutes. With a median follow-up time of 24 months, women with higher cisplatin peritoneal Cmax showed a longer PFS compared to women with low cisplatin peritoneal levels (2-years PFS=70% vs. 35%; p-value=0.054). We demonstrate for the first time that minimally invasive route enhances cisplatin peritoneal tissue uptake during HIPEC, further evaluations are needed to confirm the correlation between peritoneal cisplatin levels after HIPEC and survival. ClinicalTrials.gov Identifier: NCT01539785.
- 1 December 2018
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1042, 1-10
Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging
- 1 December 2018
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1042, 1-10
Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging
- 25 October 2018
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 90 (22) , 13257-13264
Drug-Homogeneity Index in Mass-Spectrometry Imaging
Enhancing drug penetration in solid tumors is an interesting clinical issue, of considerable importance. In pre-clinical research mass spectrometry imaging is a promising technique to visualize drug distribution in tumors in different treatment conditions and its application in this field is rapidly increasing. However, in view of the huge variability among MSI datasets, drug homogeneity is usually manually assessed by an expert and this approach is biased by inter-observer variability and lacks reproducibility. We propose a new texture-based feature, the ‘Drug Homogeneity Index (DHI)’ which provides an objective, automated measure of drug homogeneity in MSI data. A simulation study on synthetic datasets showed that previously known texture features do not give an accurate picture of intra-tumor drug distribution patterns and are easily influenced by the tumor tissue morphology. The DHI has been used to study the distribution profile of the anti-cancer drug paclitaxel in various xenograft models, either not pretreated or pretreated with anti-angiogenesis compounds. The conclusion is that drug homogeneity is better in the pretreated condition, which is in agreement with previous experimental findings published by our group. This study shows that DHI could be useful in preclinical studies as a new parameter for the evaluation of protocols for better drug penetration.
- 25 October 2018
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 90 (22) , 13257-13264
Drug-Homogeneity Index in Mass-Spectrometry Imaging
Enhancing drug penetration in solid tumors is an interesting clinical issue, of considerable importance. In pre-clinical research mass spectrometry imaging is a promising technique to visualize drug distribution in tumors in different treatment conditions and its application in this field is rapidly increasing. However, in view of the huge variability among MSI datasets, drug homogeneity is usually manually assessed by an expert and this approach is biased by inter-observer variability and lacks reproducibility. We propose a new texture-based feature, the ‘Drug Homogeneity Index (DHI)’ which provides an objective, automated measure of drug homogeneity in MSI data. A simulation study on synthetic datasets showed that previously known texture features do not give an accurate picture of intra-tumor drug distribution patterns and are easily influenced by the tumor tissue morphology. The DHI has been used to study the distribution profile of the anti-cancer drug paclitaxel in various xenograft models, either not pretreated or pretreated with anti-angiogenesis compounds. The conclusion is that drug homogeneity is better in the pretreated condition, which is in agreement with previous experimental findings published by our group. This study shows that DHI could be useful in preclinical studies as a new parameter for the evaluation of protocols for better drug penetration.
- 25 July 2018
- Published by Wiley in Macromolecular Bioscience
- Vol. 18 (10) , e1800164
Self‐Assembling PCL‐Based Nanoparticles as PTX Solubility Enhancer Excipients
The advent of nanotechnology in medicine has allowed to eliminate the toxic excipients that are often necessary to formulate lipophilic drugs in clinics. An example is paclitaxel, one of the most important chemotherapeutic drugs developed so far, where the Cremophor EL has been eliminated in the Genexol and Abraxane formulations. However, the complex procedures to synthesize these formulations hamper their cost‐effective use and, in turn, their distribution among the patient population. For this reason, a simplified method to formulate this drug directly at the bed of the patient has been adopted. It requires only the use of a syringe and it starts from a native dry amphiphilic biodegradable and biocompatible block‐copolymer obtained via the combination of the reversible addition–fragmentation chain transfer polymerization and ring‐opening polymerization. In this way, a novel paclitaxel formulation with the same drug pharmacological properties, but without the use of the Cremophor EL, can be produced. In addition, as long as these nanoparticles are engineered to act as solubility enhancers, a lower burden for its approval from the pharmaceutical regulatory agencies is also expected.
- 25 July 2018
- Published by Wiley in Macromolecular Bioscience
- Vol. 18 (10) , e1800164
Self‐Assembling PCL‐Based Nanoparticles as PTX Solubility Enhancer Excipients
The advent of nanotechnology in medicine has allowed to eliminate the toxic excipients that are often necessary to formulate lipophilic drugs in clinics. An example is paclitaxel, one of the most important chemotherapeutic drugs developed so far, where the Cremophor EL has been eliminated in the Genexol and Abraxane formulations. However, the complex procedures to synthesize these formulations hamper their cost‐effective use and, in turn, their distribution among the patient population. For this reason, a simplified method to formulate this drug directly at the bed of the patient has been adopted. It requires only the use of a syringe and it starts from a native dry amphiphilic biodegradable and biocompatible block‐copolymer obtained via the combination of the reversible addition–fragmentation chain transfer polymerization and ring‐opening polymerization. In this way, a novel paclitaxel formulation with the same drug pharmacological properties, but without the use of the Cremophor EL, can be produced. In addition, as long as these nanoparticles are engineered to act as solubility enhancers, a lower burden for its approval from the pharmaceutical regulatory agencies is also expected.
- Open Access
- 2 November 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (80) , 50981-50992
Poly(HPMA)-based copolymers with biodegradable side chains able to self assemble into nanoparticles
N-(2-Hydroxypropyl)methacrylamide (HPMA) is a water soluble monomer used in the synthesis of biocompatible and non-immunogenic polymers. In particular, poly(HPMA) can be exploited to sterically stabilize nanoparticles (NPs) suitable for the delivery of lipophilic therapeutics without the concerns related to the use of the polyethylene glycol (PEG), such as allergic reactions and the accelerated blood clearance effect. In addition, the use of the ring opening polymerization (ROP) of a lactone in the presence of an initiator that bears a double bond and a hydroxyl group is a promising way (the so called “macromonomer method”) to produce oligoester-based monomers and, in turn, to obtain biodegradable NPs via free radical polymerization. However, HPMA cannot be used as initiator being a secondary alcohol and thus hampering the control over the polymer molecular weight (MW). For this reason, in this work, a novel class of amphiphilic block copolymers that consists of a poly(HPMA) backbone and several short oligo(ε-caprolactone) side chains were produced via the adoption of the reversible addition–fragmentation chain transfer (RAFT) polymerization and the “inversion” of the macromonomer method. The oligoester was first synthesized via the ROP of ε-caprolactone in the presence of a primary alcohol and then attached to HPMA using a succinic acid unit as spacer. The NPs obtained via the self-assembly of these novel block copolymers are designed to degrade into completely water soluble poly(HPMA) chains with a MW lower than the threshold value for the renal excretion. The cytotoxicity of these novel carriers and their ability to load trabectedin, a hydrophobic anticancer therapeutic, were assessed.
- 2 November 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (80) , 50981-50992
Open AccessPoly(HPMA)-based copolymers with biodegradable side chains able to self assemble into nanoparticles
N-(2-Hydroxypropyl)methacrylamide (HPMA) is a water soluble monomer used in the synthesis of biocompatible and non-immunogenic polymers. In particular, poly(HPMA) can be exploited to sterically stabilize nanoparticles (NPs) suitable for the delivery of lipophilic therapeutics without the concerns related to the use of the polyethylene glycol (PEG), such as allergic reactions and the accelerated blood clearance effect. In addition, the use of the ring opening polymerization (ROP) of a lactone in the presence of an initiator that bears a double bond and a hydroxyl group is a promising way (the so called “macromonomer method”) to produce oligoester-based monomers and, in turn, to obtain biodegradable NPs via free radical polymerization. However, HPMA cannot be used as initiator being a secondary alcohol and thus hampering the control over the polymer molecular weight (MW). For this reason, in this work, a novel class of amphiphilic block copolymers that consists of a poly(HPMA) backbone and several short oligo(ε-caprolactone) side chains were produced via the adoption of the reversible addition–fragmentation chain transfer (RAFT) polymerization and the “inversion” of the macromonomer method. The oligoester was first synthesized via the ROP of ε-caprolactone in the presence of a primary alcohol and then attached to HPMA using a succinic acid unit as spacer. The NPs obtained via the self-assembly of these novel block copolymers are designed to degrade into completely water soluble poly(HPMA) chains with a MW lower than the threshold value for the renal excretion. The cytotoxicity of these novel carriers and their ability to load trabectedin, a hydrophobic anticancer therapeutic, were assessed.
- Open Access
- 11 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186250
Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic severe sensory peripheral neuropathy. However, despite similar co-morbidities, cancer stage, demographics and treatment schedule, patients develop oxaliplatin-induced peripheral neurotoxicity with remarkably different severity. This suggests individual genetic variability, which might be used to glean the mechanistic insights into oxaliplatin neurotoxicity. We characterized the susceptibility of different mice strains to oxaliplatin neurotoxicity investigating the phenotypic features of neuropathy and gene expression profiles in dorsal root ganglia of six genetically different mice strains (Balb-c, C57BL6, DBA/2J, AJ, FVB and CD1) exposed to the same oxaliplatin schedule. Differential gene expression in dorsal root ganglia from each mice strain were assayed using a genome-wide expression analysis and selected genes were validated by RT-PCR analysis. The demonstration of consistent differences in the phenotypic response to oxaliplatin across different strains is interesting to allow the selection of the appropriate strain based on the pre-defined read-out parameters. Further investigation of the correlation between gene expression changes and oxaliplatin-induced neurotoxicity phenotype in each strain will be useful to deeper investigate the molecular mechanisms of oxaliplatin neurotoxicity.
- 11 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186250
Open AccessSusceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic severe sensory peripheral neuropathy. However, despite similar co-morbidities, cancer stage, demographics and treatment schedule, patients develop oxaliplatin-induced peripheral neurotoxicity with remarkably different severity. This suggests individual genetic variability, which might be used to glean the mechanistic insights into oxaliplatin neurotoxicity. We characterized the susceptibility of different mice strains to oxaliplatin neurotoxicity investigating the phenotypic features of neuropathy and gene expression profiles in dorsal root ganglia of six genetically different mice strains (Balb-c, C57BL6, DBA/2J, AJ, FVB and CD1) exposed to the same oxaliplatin schedule. Differential gene expression in dorsal root ganglia from each mice strain were assayed using a genome-wide expression analysis and selected genes were validated by RT-PCR analysis. The demonstration of consistent differences in the phenotypic response to oxaliplatin across different strains is interesting to allow the selection of the appropriate strain based on the pre-defined read-out parameters. Further investigation of the correlation between gene expression changes and oxaliplatin-induced neurotoxicity phenotype in each strain will be useful to deeper investigate the molecular mechanisms of oxaliplatin neurotoxicity.